Sword & Shield Pharma Ltd. CIN: L24231GJ1995PLC024809

Security Code: 531637 Security ID: SWORDNSH

13th February, 2019

To, The Listing Compliance Department, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

Ref: Reg. 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Subject: Outcome of the Board Meeting held today and submission of Unaudited Financial results for the quarter ended 31st December, 2018

Dear Sir/ Madam,

In reference to captioned subject, we hereby inform you that the Board of Directors of the Company, in their Board Meeting held today, i.e. on Wednesday, 13th February, 2019 commenced at 09.00 am (GMT-4)/ 6.30 PM (IST) and concluded at 09.30 am (GMT-4)/7.00 PM (IST) has Considered, approved and took on record the unaudited financial results for the quarter and nine months ended on 31st December, 2018 along with Limited Review Report.

You are requested to take note of the same.

Thanking You,

Yours Faithfully,

For, SWORD AND SHIELD PHARMA I co al an **POOJA KADAM** Company Secretary & Compliance Office (ACS: 43019) 76,11995

B. K. PATEL & CO Chartered Accountants

401, VRAJ Valencia, Behind Mahindra Show Room, Near Sola Overbridge, S.G.Highway, Sola, AHMEDABAD – 380 060. Gujarat PHONES : 079 – 2970 0973 Email : <u>bkpatelandco@gmail.com</u>

Limited Review Report

To, The Board of Directors, Sword & Shield Pharma Limited. Ahmedabad

We have reviewed the accompanying statement of Un-Audited Financial Results (the statements) together with the relevant notes thereon of **Sword & Shield Pharma Limited**, Ahmedabad for the quarter and nine months ended on **December 31, 2018** prepared by the Company in pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a review report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by independent auditor of entity' issued by The Institute of Chartered Accountants of India which requires that we plan and perform the review to obtain moderate assurance as to whether the financial information's are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. A review is subsequently less in scope than an audit conducted in accordance with standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified during the course an Audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with Indian accounting standards as specified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, or that it contains any material misstatement.



For, B. K. PATEL & CO Chartered Accountants Firm Regn No. 112647W

K. D.Patel Parther Membership No.39919

13-2-2019 Ahmedabad

	SWORD AND SHIELD PHARMA LIMITED CIN: L24231GJ1995PLC024809							
ill your	Registered Office: 55, World Business House, Near Parimal Garden, Ambawadi,							
and the		nedabad – 380 (1.1			
2.7		w.swordnshield	•					
Webs		ct: +91 98250 7	· · · · · · · · · · · · · · · · · · ·					
1.00	Un-Audited Financial Results			or 21 2018		1	12/2012	
31.2.1		cial Results – In		per 31, 2018				
200	Finan	cial Results - III	u-A3	- interest		(A)	mount in LAK	
, New .	e transmission and the second s	r	I	the second second	19 A.	a. S. Sulah I	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	
1 240	444 (A)	3 months	3 months	3 months	9 months	9 months	Previous	
13 1 1	Particulars	The second se		and the second second	2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	ended (dd-	Financial Ye	
1.24		mm-yyyy)	тт-уууу)	mm-yyyy)	mm-yyyy	тт-уууу	ended	
A	Date of start of reporting period	1-Oct-18	1-Jul-18	1-Oct-17	1-Apr-18	1-Apr-17	1-Apr-17	
В	Date of end of reporting period	31-Dec-18	30-Sep-18	31-Dec-17	31-Dec-18	31-Dec-17	31-Mar-18	
С	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone	Standalone	Standalon	
Part		10 10 10 10 10 10 10 10 10 10 10 10 10 1	Numero a construction	a we brief and			THE REAL PROPERTY.	
1	Income	1.16118	Towns Gtor	SPANSE STA	a la contrata	Real States	al a	
	Revenue from operations	0.702	0.477	0.518	1.179	2.895	2.2	
	Other income	0.006	0.003	0.021	0.010	0.035	0.0	
	Total income	0.708	0.480	0.539	1.189	2.929	2.9	
2		<u></u>		- a series to be a series to	146	北京学校の行うであるよう	115 25 3	
(a)	Cost of materials consumed	0.000	0.000	0.000	0.000	0.000	0.0	
(b)		0.000	0.000	0.000	0.000	0.000	0.	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in- trade	0.000	0.000	0.000	0.000	0.000	0.0	
(d)	Employee benefit expense	0.872	0.939	1.212	2.540	3.279	4.	
(e)	Finance costs	0.000	0.000	0.000	0.000	0.006	0.	
(f)	Depreciation, depletion and amortisation expense	0.000	0.000	0.000	0.000	0.000	0.0	
(f)	Other Expenses							
101	Other Expenses	0.775	0.968	2.775	5.426	11.618	14.0	
124	Total other expenses	0.775	0.968	2.775	5.426	11.618	14.0	
13		1.647	1.907	3.987	7.967	14.904	18.6	
4	Exceptional items and tax	-0.939	-1.427	-3.449	-6.778	-11.974	-15.6	
137		0.000	0.000	0.000	0.000	0 000	0.4	

5	Total profit before tax	-0.939	-1.427	-3.449	-6.778	-11.974	-16.066
7	Tax expense	Charles where	11. 11. 55.5	Novilar + Lands +	1125666217		Star Carl
8	Current tax	0.000	0.000	0.000	0.000	0.000	0.000
9	Deferred tax	0.000	0.000	0.000	0.000	0.000	0.000
10	Total tax expenses	0.000	0.000	0.000	0.000	0.000	0.000
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.000	0.000	0.000	0.000	0.000	0.000
14	Net Profit Loss for the period from continuing operations	-0.939	-1.427	-3.449	-6.778	-11.974	-16.066
15	Profit (loss) from discontinued operations before tax	0.000	0.000	0.000	0.000	0 000	0.000
16	Tax expense of discontinued operations	0.000	0.000	0.000	0.000	0.000	0.000
17	Net profit (loss) from discontinued operation after tax	0.000	0.000	0.000	0.000	0.000	0.000
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.000	0.000	0.000	0.000	0.000	0.000
21	Total profit (loss) for period	-0.939	-1.427	-3.449	-6.778	-11.974	-16.066
22	Other comprehensive income net of taxes	0.000	0.000	0.000	0.000	0.000	0.000
23	Total Comprehensive Income for the period	0.000	0.000	0.000	0.000	0.000	0.000
24	Total profit or loss, attributable to	LENDERCES			Sale States		take the second
	Profit or loss, attributable to owners of parent	Managerson 3	1000 1000 E		A State of the second second	14	State And a state
	Total profit or loss, attributable to non-controlling interests	「お牛肉」	中国にためが地位	the second second	ATTENDAY.	Prove Standard	网络拉达马马
25	Total Comprehensive income for the period attributable to	Sallen Press	1			States and the	Bartin all
	Comprehensive income for the period attributable to owners of parent	0.000	0.000	0.000	0.000	0.000	0.000
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0.000	0.000	0.000	0.000	0.000	0.000
26	Details of equity share capital		1. 1. 1. 1.	direction in the second	2-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1		and a starting of
	Paid-up equity share capital	51506000.00	51506000.00	51506000.00	51506000.00	51506000 00	49877060.0
	Face value of equity share capital	10.00	10.00	10.00	10.00	10.00	10.0
27	Details of debt securities	••••		A	The second	A 18 18 1940	B.T. Partie
	Paid-up debt capital				350 - 560	1000	
	Face value of debt securities						10 10 TO
28	Reserves excluding revaluation reserve			1.1	~		-495.9
29	Debenture redemption reserve					Core 2 and	455.5
30	Earnings per share						Card and the state
N	Earnings per equity share for continuing operations	1 2010		45.		11. 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	ASSANT STOR
	Basic earnings (loss) per share from continuing operations	0.000	0.000	0.000	0.000	0.000	0.00
2.13	busic continues per share non containing operations						

AHMEDASA ANTS

	Basic earnings (loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
	Diluted earnings (loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
i	Earnings per equity share				A Caller		Calendary
	Basic earnings (loss) per share from continuing and discontinued operations		*				
	Diluted earnings (loss) per share from continuing and discontinued operations						
31	Debt equity ratio	CALL STREET, ST				Star Barry	1966 1 1 1 1 1
32	Debt service coverage ratio		and the second	Barren bered	THE REPORT	Street of the	
33	Interest service coverage ratio	State State	这些利益的时候				State of the second second

1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on 13th February, 2019

2. The Company adopted Indian Accounting Standards (IndAS) from April 1, 2017 as per road map released by Ministry of Corporate Affairs (MCA). Reconciliation of Net Profit after

tax as previously reported under Indian GAAP and IndAS for the quarter ended December 31, 2018 is as follows:

	31-12-2018
	Unaudited
Net Profit as per Previous Indian GAAP	-0.939
Net Profit as per IndAS	-0.939

The Limited Review of the results has been completed by the Statutory Auditors of the Company.

4. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".

5. The financial results for the guarter ended 30 September 2018 are also Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view. This information has not been subjected to limited review or audit.

6. Previous guarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current guarter.

7. Results are available at Company's website www.swordnshieldpharma.com and also at www.bseindia.com.

For SWORD & SHIELD PHARMA LIMITED

AMAYEDAGA

PRAVINBHAI PATEL MANAGING DIRECTOR

DIN: 01877446

Place Pennyslavania Date 13/02/2019

NOTES